Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 04 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Amantadine Extended-Release Capsules. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the capsules, which are used to treat dyskinesia in Parkinson's disease patients. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had annual sales of a specific amount in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases